GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (MEX:MRK) » Definitions » Cyclically Adjusted Price-to-FCF

Merck (MEX:MRK) Cyclically Adjusted Price-to-FCF : 16.48 (As of Jun. 04, 2025)


View and export this data going back to 1946. Start your Free Trial

What is Merck Cyclically Adjusted Price-to-FCF?

As of today (2025-06-04), Merck's current share price is MXN1479.00. Merck's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was MXN89.73. Merck's Cyclically Adjusted Price-to-FCF for today is 16.48.

The historical rank and industry rank for Merck's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

MEX:MRK' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 16.4   Med: 23.72   Max: 34.1
Current: 17.32

During the past years, Merck's highest Cyclically Adjusted Price-to-FCF was 34.10. The lowest was 16.40. And the median was 23.72.

MEX:MRK's Cyclically Adjusted Price-to-FCF is ranked better than
75.08% of 325 companies
in the Drug Manufacturers industry
Industry Median: 31.58 vs MEX:MRK: 17.32

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Merck's adjusted free cash flow per share data for the three months ended in Mar. 2025 was MXN9.473. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is MXN89.73 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Merck Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Merck's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Cyclically Adjusted Price-to-FCF Chart

Merck Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.50 22.76 28.97 28.14 22.37

Merck Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.52 30.50 26.87 22.37 20.16

Competitive Comparison of Merck's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted Price-to-FCF falls into.


;
;

Merck Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Merck's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=1479.00/89.73
=16.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Merck's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=9.473/134.9266*134.9266
=9.473

Current CPI (Mar. 2025) = 134.9266.

Merck Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 13.356 100.684 17.898
201509 17.845 100.392 23.984
201512 22.933 99.792 31.007
201603 11.665 100.470 15.665
201606 8.123 101.688 10.778
201609 17.781 101.861 23.553
201612 22.890 101.863 30.320
201703 -0.361 102.862 -0.474
201706 19.206 103.349 25.074
201709 -10.728 104.136 -13.900
201712 23.769 104.011 30.834
201803 4.726 105.290 6.056
201806 20.400 106.317 25.890
201809 14.947 106.507 18.935
201812 19.851 105.998 25.269
201903 5.522 107.251 6.947
201906 17.086 108.070 21.332
201909 25.077 108.329 31.234
201912 27.719 108.420 34.496
202003 -2.569 108.902 -3.183
202006 25.485 108.767 31.614
202009 6.337 109.815 7.786
202012 20.158 109.897 24.749
202103 5.704 111.754 6.887
202106 11.787 114.631 13.874
202109 29.392 115.734 34.266
202112 30.937 117.630 35.486
202203 29.643 121.301 32.973
202206 25.132 125.017 27.124
202209 35.419 125.227 38.163
202212 25.105 125.222 27.051
202303 2.346 127.348 2.486
202306 18.494 128.729 19.384
202309 46.626 129.860 48.445
202312 -4.963 129.419 -5.174
202403 14.541 131.776 14.889
202406 34.897 132.554 35.522
202409 65.929 133.029 66.869
202412 20.675 133.157 20.950
202503 9.473 134.927 9.473

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Merck  (MEX:MRK) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Merck Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Merck's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck Business Description

Industry
Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck Headlines

From GuruFocus

Merck Announces Third-Quarter 2025 Dividend

By Business Wire 05-27-2025